MAX and MYC: A Heritable Breakup
- 1 July 2012
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (13), 3119-3124
- https://doi.org/10.1158/0008-5472.can-11-3891
Abstract
The overexpression of MYC, which occurs in many tumors, dramatically disrupts the equilibrium between activation and repression of the oncogenic MYC/MYC-associated protein X (MAX)/MAX dimerization protein 1 (MXD1) network, favoring MYC–MAX complexes and thereby impairing differentiation and promoting cell growth. Although for some time it has appeared that MAX is necessary for both the activation and repression of the axis, recent evidence shows that MYC retains considerable biologic function in the absence of MAX. The presence of germline MAX mutations in patients with hereditary pheochromocytoma supports the predominant role of MAX as a negative regulator of the network and suggests that MYC deregulation plays a role in hereditary cancer predisposition. This finding also confirms the importance of impairment of the MYC/MAX/MXD1 axis in the development of aggressive neural tumors, because MYCN overexpression is an established genetic hallmark of malign neuroblastoma, and it is likely that MXI1 plays a relevant role in the development of medulloblastoma and glioblastoma. Finally, the likely malignant behavior of tumors with mutations in MAX points to MYC as a candidate therapeutic target in the treatment of metastatic pheochromocytoma. Cancer Res; 72(13); 3119–24. ©2012 AACR.This publication has 40 references indexed in Scilit:
- Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastomaBritish Journal of Cancer, 2011
- Targeting MYC dependence in cancer by inhibiting BET bromodomainsProceedings of the National Academy of Sciences of the United States of America, 2011
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- Germline mutations in TMEM127 confer susceptibility to pheochromocytomaNature Genetics, 2010
- Comparison of Primary Neuroblastoma Tumors and Derivative Early-Passage Cell Lines Using Genome-Wide Single Nucleotide Polymorphism Array AnalysisCancer Research, 2009
- Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1Proceedings of the National Academy of Sciences of the United States of America, 2008
- Restoration of p53 function leads to tumour regression in vivoNature, 2007
- Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switchProceedings of the National Academy of Sciences of the United States of America, 2006
- MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancerNature, 2004
- Analysis of the max-binding protein MNT in human medulloblastomasInternational Journal of Cancer, 1999